Finance

Lists
VTGN:NASDAQ
Vistagen Therapeutics Inc
0,17 $
+0,30%
(+0,00050) 1D
0,17 $
-0,60% (-0,0010)
Pre-market
Closed: 3 қар., 16:00:01 GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for VTGN...
Open
0,17 $
High
0,18 $
Low
0,17 $
Mkt. cap
7,35 млн
Avg. vol.
21,30 млн
Volume
3,33 мың
52-wk high
5,14 $
52-wk low
0,17 $
EPS
-1,68 $
Beta
0,49
Shares outstanding
44,38 млн
No. of employees
41
Open
0,17 $
High
0,18 $
Low
0,17 $
Mkt. cap
7,35 млн
Avg. vol.
21,30 млн
Volume
3,33 мың
52-wk high
5,14 $
52-wk low
0,17 $
EPS
-1,68 $
Beta
0,49
Shares outstanding
44,38 млн
No. of employees
41
News stories
From web sources and news partners
Yahoo Finance
Yahoo Finance
·
29 минут бұрын
Goldman Sachs Research Expects Slower S&P 500 Earnings Growth in 2027 (Only 18%). Can the Bull Market Keep Going?
marketscreener.com
marketscreener.com
·
10 минут бұрын
McGrath RentCorp(NasdaqGS: MGRC) added to S&P 1000
TradingView
TradingView
·
38 минут бұрын
US Futures Soar
The Motley Fool
The Motley Fool
·
1 сағат бұрын
3 Nasdaq-100 Stocks That Can Double, According to Wall Street
About Vistagen Therapeutics Inc
CEO-
Employees41
Founded1998
HeadquartersSouth San Francisco, Калифорния, Америка Құрама Штаттары
Sector-
Industry-
Websitevistagen.com
Analyst ratings
Based on 1 analyst giving stock ratings to VTGN in the past 3 months
Hold
Buy
0
Hold
1
Sell
0
12-month forecast
Based on 1 Wall Street analyst offering 12-month price targets for VTGN in the last 3 months
Highest
Current 0,17 $
(-100,00%)
Average
(-100,00%)
Lowest
(-100,00%)
Analyst
Recommendation
Action
Price target
Projected
Date
Myles Minter
William Blair
Hold
Maintained
-
-
09/23/2026
Paul Matteis
Stifel Nicolaus
Hold
Maintained
1,00 $
+495,2%
07/06/2026
Andrew Tsai
Jefferies
Hold
Downgraded
0,90 $
+435,7%
12/17/2025
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
2025 ж. қыр.
2025 ж. жел.
2026 ж. нау.
2026 ж. мау.
Revenue
258,00 м.
303,00 м.
465,00 м.
1,48 млн
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
15,92 млн
14,22 млн
13,06 млн
10,91 млн
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
4,40 млн
5,63 млн
4,12 млн
3,92 млн
Operating expense
20,31 млн
19,85 млн
17,18 млн
14,82 млн
Total operating expenses
20,31 млн
19,85 млн
17,18 млн
14,82 млн
Operating income
-20,05 млн
-19,55 млн
-16,72 млн
-13,35 млн
Other non operating income
6,00 мың
-
-2,00 мың
-1,00 мың
EBT including unusual items
-19,42 млн
-18,90 млн
-16,27 млн
-13,03 млн
EBT excluding unusual items
-19,42 млн
-18,90 млн
-16,27 млн
-13,03 млн
Income tax expense
-
-
7,00 мың
-
Effective tax rate
-
-
-0,04%
-
Other operating expenses
-
-
-
-
Net income
-19,42 млн
-18,90 млн
-16,27 млн
-13,03 млн
Net profit margin
-7 525,97%
-6 237,29%
-3 499,78%
-882,79%
Earnings per share
-0,54
-0,45
-0,37
-0,30
Interest and investment income
630,00 м.
647,00 м.
452,00 м.
319,00 м.
Interest expense
-
-
-
-
Net interest expenses
630,00 м.
647,00 м.
452,00 м.
319,00 м.
Depreciation and amortization charges
-
-
-
-
EBITDA
-20,00 млн
-19,49 млн
-16,66 млн
-13,30 млн
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google қолданбалары